CFD 属于复杂的高风险金融工具，其杠杆作用可能导致投资者迅速亏损。 84% 的散户投资者因进行 CFD 交易遭受资金损失。 请您谨慎考虑自己是否了解 CFD 操作，以及是否能够接受高额亏损的风险。
US 简体中文
國家 • United States
    實體 • The products and services listed on this website are not available in this location.
    English العَرَبِيَّة Bahasa Indonesia Български Čeština Dansk Deutsch Eesti ελληνικά Español Français Hrvatski Italiano Latviešu Lietuvių Magyar Nederlands Polski Português Română Русский Slovenčina Slovenščina Suomi Svenska Tiếng Việt ไทย 简体中文 繁體中文

    交易 VBI Vaccines Inc. - VBIV CFD

    2.90
    2.68%
    • 概括
    • 历史数据
    • 活动
    • 收入报表
    • 资产负债表
    • 现金流
    • 所有权
    交易条件
    价差 0.08
    多头隔夜费

    Long position overnight fee

    Margin. Your investment $1,000.00
    隔夜费用 -0.025457 %
    Charges from borrowed part ($-1.02)
    Trade size with leverage ~ $5,000.00
    Money from leverage ~ $4,000.00
    前往平台
    		-0.025457%
    空头隔夜费

    Short position overnight fee

    Margin. Your investment $1,000.00
    隔夜费用 0.003235 %
    Charges from borrowed part ($0.13)
    Trade size with leverage ~ $5,000.00
    Money from leverage ~ $4,000.00
    前往平台
    		0.003235%
    隔夜费时间 21:00 (UTC)
    最小交易量 1
    货币 USD
    保证金 20%
    上市交易所 United States of America
    交易费 0%

    *Information provided by Capital.com

    VBI Vaccines Inc ESG Risk Ratings

    High Medium Low Negligible

    ‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

    关键数据
    前收盘价* 2.98
    开仓* 2.88
    1 年变化* 223.6%
    日范围* 2.84 - 2.94
    52 周范围 2.35-40.50
    平均交易量（10 天） 73.33K
    平均交易量（3 个月) 2.26M
    市值 24.75M
    市盈率 -100.00K
    流通股 8.61M
    收入 1.44M
    EPS -13.92
    股息（收益率 %） N/A
    贝塔 1.83
    下一个财报发布日期 Aug 7, 2023

    所有数据都是由Refinitiv提供的， 除了标有星号的数据， 这是*由 Capital.com 提供的数据

    • Last Week
    • Last Month
    • Last Year
    • Last two Years
    • Max
    • Daily
    • Weekly
    • Monthly
    Date 平仓 Change Change (%) 開倉 High Low
    May 30, 2023 2.98 0.16 5.67% 2.82 3.04 2.79
    May 26, 2023 2.84 0.11 4.03% 2.73 2.85 2.69
    May 25, 2023 2.72 -0.22 -7.48% 2.94 2.99 2.50
    May 24, 2023 2.94 -0.17 -5.47% 3.11 3.16 2.87
    May 23, 2023 3.21 0.18 5.94% 3.03 3.29 3.03
    May 22, 2023 3.09 0.06 1.98% 3.03 3.22 2.94
    May 19, 2023 3.00 0.18 6.38% 2.82 3.02 2.81
    May 18, 2023 2.80 -0.09 -3.11% 2.89 2.92 2.68
    May 17, 2023 2.90 -0.03 -1.02% 2.93 2.96 2.83
    May 16, 2023 2.96 -0.06 -1.99% 3.02 3.06 2.88
    May 15, 2023 3.03 0.05 1.68% 2.98 3.11 2.96
    May 12, 2023 2.94 -0.12 -3.92% 3.06 3.10 2.77
    May 11, 2023 3.06 -0.05 -1.61% 3.11 3.17 3.01
    May 10, 2023 3.13 0.02 0.64% 3.11 3.22 3.11
    May 9, 2023 3.19 0.35 12.32% 2.84 3.26 2.79
    May 8, 2023 2.90 0.17 6.23% 2.73 2.90 2.63
    May 5, 2023 2.72 0.03 1.12% 2.69 2.75 2.63
    May 4, 2023 2.66 -0.22 -7.64% 2.88 2.95 2.62
    May 3, 2023 2.90 0.11 3.94% 2.79 2.90 2.78
    May 2, 2023 2.83 -0.05 -1.74% 2.88 2.93 2.72

    VBI Vaccines Inc. Events

    时间（协调世界时） (UTC) 国家/地区 事件
    Thursday, June 22, 2023

    时间（协调世界时） (UTC)

    15:30

    国家/地区

    US

    事件

    VBI Vaccines Inc Annual Shareholders Meeting
    VBI Vaccines Inc Annual Shareholders Meeting

    Forecast

    -

    Previous

    -
    Friday, June 23, 2023

    时间（协调世界时） (UTC)

    15:00

    国家/地区

    US

    事件

    VBI Vaccines Inc Annual Shareholders Meeting
    VBI Vaccines Inc Annual Shareholders Meeting

    Forecast

    -

    Previous

    -
    Monday, August 7, 2023

    时间（协调世界时） (UTC)

    12:30

    国家/地区

    US

    事件

    Q2 2023 VBI Vaccines Inc Earnings Release
    Q2 2023 VBI Vaccines Inc Earnings Release

    Forecast

    -

    Previous

    -
    Wednesday, November 8, 2023

    时间（协调世界时） (UTC)

    13:00

    国家/地区

    US

    事件

    Q3 2023 VBI Vaccines Inc Earnings Release
    Q3 2023 VBI Vaccines Inc Earnings Release

    Forecast

    -

    Previous

    -
    查看所有活動
    • 年度
    • 每季度
    2022 2021 2020 2019 2018
    总收入 1.082 0.631 1.061 2.221 3.355
    收入 1.082 0.631 1.061 2.221 3.355
    收入成本，共计 11.276 10.77 9.168 7.904 4.509
    毛利 -10.194 -10.139 -8.107 -5.683 -1.154
    总营业费用 83.074 68.663 44.678 54.62 63.763
    销售/一般/行政费用，总计 56.12 38.335 20.651 14.092 14.509
    研究与开发 15.506 19.558 14.859 26.332 38.443
    营业收入 -81.992 -68.032 -43.617 -52.399 -60.408
    利息收入（费用），非经营净值 -31.311 -1.721 -2.613 -2.414 -3.192
    税前净收入 -113.303 -69.753 -46.23 -54.813 -63.6
    税后净收入 -113.303 -69.753 -46.23 -54.813 -63.6
    未计算非常项目前的净收益 -113.303 -69.753 -46.23 -54.813 -63.6
    净收入 -113.303 -69.753 -46.23 -54.813 -63.6
    普通股股东可获收益 (不含非经常性项目) -113.303 -69.753 -46.23 -54.813 -63.6
    普通股股东可获收益 (含非經常性項目) -113.303 -69.753 -46.23 -54.813 -63.6
    摊薄净收入 -113.303 -69.753 -46.23 -54.813 -63.6
    摊薄后加权平均股 8.60772 8.49739 7.27491 3.98115 2.18804
    扣除特别项目的每股摊薄盈利 -13.163 -8.20876 -6.35472 -13.7681 -29.0671
    每股正常摊薄盈利 -13.143 -8.20876 -6.35472 -12.1877 -26.1869
    异常费用（收入） 0.172 0 6.292 6.302
    Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
    总收入 0.485 0.293 0.317 0.346 0.126
    收入 0.485 0.293 0.317 0.346 0.126
    收入成本，共计 3.559 3.328 2.672 2.522 2.754
    毛利 -3.074 -3.035 -2.355 -2.176 -2.628
    总营业费用 19.994 21.732 22.047 23.249 16.046
    销售/一般/行政费用，总计 13.284 15.886 14.22 15.084 10.93
    研究与开发 3.151 2.518 4.983 5.643 2.362
    营业收入 -19.509 -21.439 -21.73 -22.903 -15.92
    利息收入（费用），非经营净值 -8.242 0.298 -3.479 -22.796 -5.334
    税前净收入 -27.751 -21.141 -25.209 -45.699 -21.254
    税后净收入 -27.751 -21.141 -25.209 -45.699 -21.254
    未计算非常项目前的净收益 -27.751 -21.141 -25.209 -45.699 -21.254
    净收入 -27.751 -21.141 -25.209 -45.699 -21.254
    普通股股东可获收益 (不含非经常性项目) -27.751 -21.141 -25.209 -45.699 -21.254
    普通股股东可获收益 (含非經常性項目) -27.751 -21.141 -25.209 -45.699 -21.254
    摊薄净收入 -27.751 -21.141 -25.209 -45.699 -21.254
    摊薄后加权平均股 8.60854 8.60772 8.60772 8.60772 8.6077
    扣除特别项目的每股摊薄盈利 -3.22366 -2.45605 -2.92865 -5.30907 -2.46919
    Dividends per Share - Common Stock Primary Issue 0 0 0 0
    每股正常摊薄盈利 -3.22366 -2.45605 -2.90867 -5.30907 -2.46919
    异常费用（收入） 0 0.172
    • 年度
    • 每季度
    2022 2021 2020 2019 2018
    流动资产总额 77.69 130.284 132.041 46.963 61.731
    现金和短期投资 62.629 121.694 119.101 44.213 59.27
    Cash 62.629 121.694 93.825 44.213 59.27
    应收账款总额，净额 4.127 1.446 0.077 0.201 0.056
    Accounts Receivable - Trade, Net 0.094 0.008 0.077 0.201 0.056
    Total Inventory 6.599 2.576 2.152 1.075 0.911
    Other Current Assets, Total 2.026 2.195 9.142 0.45 0.512
    Total Assets 155.086 210.276 209.372 122.201 137.605
    Property/Plant/Equipment, Total - Net 15.569 14.381 12.275 11.654 8.525
    Property/Plant/Equipment, Total - Gross 23.55 19.34 15.885 14.414 10.936
    Accumulated Depreciation, Total -7.981 -4.959 -3.61 -2.76 -2.411
    Goodwill, Net 2.127 2.261 2.261 2.208 8.265
    Intangibles, Net 58.345 62.091 62.156 60.756 58.249
    Long Term Investments
    Other Long Term Assets, Total 1.355 1.259 0.639 0.62 0.835
    Total Current Liabilities 36.942 32.586 17.348 29.757 23.377
    Accounts Payable 12.973 4.28 3.734 1.127 6.055
    Notes Payable/Short Term Debt 0 0 0 0 0
    Other Current Liabilities, Total 9.15 12.172 1.437 1.712 4.165
    Total Liabilities 90.923 66.394 37.667 33.946 39.472
    Total Long Term Debt 48.888 28.441 16.329 0 12.927
    Long Term Debt 48.888 28.441 16.329 0 12.927
    Deferred Income Tax
    Other Liabilities, Total 5.093 5.367 3.99 4.189 3.168
    Total Equity 64.163 143.882 171.705 88.255 98.133
    Common Stock 442.312 442.235 403.528 284.965 246.417
    Additional Paid-In Capital 90.02 81.583 75.53 66.43 63.449
    Retained Earnings (Accumulated Deficit) -489.609 -378.371 -308.618 -262.388 -207.575
    Other Equity, Total 21.44 -1.565 1.265 -0.752 -4.158
    Total Liabilities & Shareholders’ Equity 155.086 210.276 209.372 122.201 137.605
    Total Common Shares Outstanding 8.60772 8.60748 8.23381 5.94131 3.24447
    Prepaid Expenses 2.309 2.373 1.569 1.024 0.982
    Accrued Expenses 14.819 16.134 12.177 12.073 12.057
    Current Port. of LT Debt/Capital Leases 0 14.845 1.1
    短期投资 0 25.276
    Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
    流动资产总额 51.836 77.69 96.216 92.752 112.347
    现金和短期投资 40.392 62.629 83.55 82.414 101.337
    Cash 40.392 62.629 83.55 82.414 101.337
    短期投资
    应收账款总额，净额 1.484 4.127 2.482 2.448 2.871
    Accounts Receivable - Trade, Net 0.281 0.094 0.132 0.135 0.102
    Total Inventory 6.768 6.599 5.796 4.05 4.057
    Prepaid Expenses 2.419 2.309 2.73 1.685 2.167
    Other Current Assets, Total 0.773 2.026 1.658 2.155 1.915
    Total Assets 128.461 155.086 172.01 172.161 194.006
    Property/Plant/Equipment, Total - Net 14.682 15.569 14.614 14.397 14.692
    Goodwill, Net 2.132 2.127 2.104 2.237 2.303
    Intangibles, Net 58.5 58.345 57.727 61.379 63.218
    Other Long Term Assets, Total 1.311 1.355 1.349 1.396 1.446
    Total Current Liabilities 29.573 36.942 34.681 40.532 33.991
    Accounts Payable 9.837 12.973 11.666 5.617 3.927
    Accrued Expenses 12.182 14.819 13.5 15.067 14.673
    Notes Payable/Short Term Debt 0 0 0 0 0
    Other Current Liabilities, Total 7.554 9.15 9.515 11.068 10.647
    Total Liabilities 83.439 90.923 88.193 66.603 64.442
    Total Long Term Debt 49.359 48.888 48.418 21.163 24.788
    Long Term Debt 49.359 48.888 48.418 21.163 24.788
    Other Liabilities, Total 4.507 5.093 5.094 4.908 5.663
    Total Equity 45.022 64.163 83.817 105.558 129.564
    Common Stock 442.322 442.312 442.3 442.286 442.272
    Additional Paid-In Capital 92.021 90.02 87.705 83.757 81.314
    Retained Earnings (Accumulated Deficit) -517.36 -489.609 -468.468 -443.259 -397.56
    Other Equity, Total 28.039 21.44 22.28 22.774 3.538
    Total Liabilities & Shareholders’ Equity 128.461 155.086 172.01 172.161 194.006
    Total Common Shares Outstanding 8.60854 8.60772 8.60772 8.60772 8.60772
    Current Port. of LT Debt/Capital Leases 8.78 4.744
    • 年度
    • 每季度
    2022 2021 2020 2019 2018
    净收入/起跑线 -113.303 -69.753 -46.23 -54.813 -63.6
    经营活动产生的现金 -73.695 -39.908 -47.05 -48.712 -45.533
    经营活动产生的现金 2.061 1.835 1.652 1.204 0.542
    Deferred Taxes 0
    非现金物品 40.208 12.801 7.666 11.525 5.053
    已付现金利息 3.231 2.039 1.608 2.033 1.98
    营运资金的变化 -2.661 15.209 -10.138 -6.628 12.472
    投资活动产生的现金 -4.344 23.156 -26 -3.673 -5.993
    资本支出 -4.344 -1.995 -1 -3.673 -5.993
    其他投资现金流量项目，总计 0 25.151 -25 0
    融资活动产生的现金 19.449 44.293 122.392 37.415 43.617
    股票的发行（报废），净额 0.012 33.382 124.325 40.25 46.623
    债务的发行（退还），净额 20 12 4.7
    外汇效应 -0.475 0.328 0.27 -0.087 -0.515
    现金净变化 -59.065 27.869 49.612 -15.057 -8.424
    融资现金流项目 -0.563 -1.089 -6.633 -2.835 -3.006
    Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
    Net income/Starting Line -27.751 -113.303 -92.162 -66.953 -21.254
    Cash From Operating Activities -21.656 -73.695 -54.649 -37.375 -19.925
    Cash From Operating Activities 0.508 2.061 1.541 1.015 0.473
    Non-Cash Items 9.639 40.208 38.591 32.47 7.429
    Cash Interest Paid 1.437 3.231 2.067 1.248 0.604
    Changes in Working Capital -4.052 -2.661 -2.619 -3.907 -6.573
    Cash From Investing Activities -0.534 -4.344 -2.892 -1.592 -0.515
    Capital Expenditures -0.534 -4.344 -2.892 -1.592 -0.515
    Cash From Financing Activities 0 19.449 19.449 0.012 0.012
    Financing Cash Flow Items -0.563 -0.563 0 0
    Issuance (Retirement) of Stock, Net 0 0.012 0.012 0.012 0.012
    Issuance (Retirement) of Debt, Net 0 20 20 0
    Foreign Exchange Effects -0.047 -0.475 -0.052 -0.325 0.071
    Net Change in Cash -22.237 -59.065 -38.144 -39.28 -20.357
    Other Investing Cash Flow Items, Total 0 0 0

    为什么选择 Capital.com？让我们的数字来说话。

    Capital.com Group

    530K+

    交易者

    87K+

    每月活跃客户

    $46M+

    每月投资额

    $31M+

    每月提取金额

    交易计算器

    如果您在特定日期（选择一个日期）开立差价合约交易并在不同日期（选择一个日期）关闭交易，计算您的假设盈亏。

    交易佣金
    0
    • 1:1
    杠杆
    1:1
    • 20
    • 100
    • 500
    • 1000
    • 10000
    投资
    交易规模（杠杆 x 投资）：
    開倉

    平仓

    做空 做多
    過去的表現並不是未來結果的可靠指標
    盈利/盈利/亏损

    VBI Vaccines Inc. Company profile

    关于 VBI Vaccines Inc

    VBI疫苗公司（VBI）是一家生物制药公司。 VBI开发的候选疫苗模仿病毒的自然表现，旨在激发人类免疫系统的先天力量。 VBI专注于瞄准和克服传染性疾病，包括乙型肝炎、冠状病毒和巨细胞病毒（CMV），以及包括胶质母细胞瘤（GBM）在内的侵袭性癌症。 公司的产品包括3个抗原的乙肝病毒（HBV）候选疫苗；VBI-2900，这是一个冠状病毒疫苗项目（VBI-2901、VBI-2902、VBI-2905）；VBI-1501，这是预防性的CMV候选疫苗；VBI-2601，这是HBV免疫治疗候选疫苗，以及VBI-1901GBM。 公司正在进行GBM疫苗免疫治疗候选人VBI-1901的I/IIa期临床研究。 公司还在进行COVID-19疫苗候选者VBI-2902的一期临床研究，以及COVID-19疫苗候选者VBI-2905针对Beta变体的临床研究。

    Industry: Biotechnology & Medical Research (NEC)

    160 Second Street
    Cambridge
    CAMBRIDGE
    MASSACHUSETTS 02142
    US

    收入报表

    • Annual
    • Quarterly

    人们也观看

    Oil - Crude

    68.57 Price
    -1.520% 1D Chg, %
    多头隔夜费 -0.0208%
    空头隔夜费 -0.0011%
    隔夜费时间 21:00 (UTC)
    价差 0.03

    BTC/USD

    27,089.05 Price
    -2.570% 1D Chg, %
    多头隔夜费 -0.0616%
    空头隔夜费 0.0137%
    隔夜费时间 21:00 (UTC)
    价差 60.00

    US100

    14,309.70 Price
    -0.480% 1D Chg, %
    多头隔夜费 -0.0255%
    空头隔夜费 0.0032%
    隔夜费时间 21:00 (UTC)
    价差 1.8

    Gold

    1,966.34 Price
    +0.390% 1D Chg, %
    多头隔夜费 -0.0089%
    空头隔夜费 0.0006%
    隔夜费时间 21:00 (UTC)
    价差 0.30

    还在找一位您可以信任的经纪商吗？

    加入成为全球530,000万多名交易者的一份子，选择利用Capital.com进行交易吧。

    1. 创建和验证您的账户 2. 进行存款 3. 找到适合您的交易